ESMO 2023 | TALAPRO-2: exposure-safety of talazoparib + enzalutamide in mCRPC

Arun Azad, PhD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the exposure safety and efficacy results from the Phase III TALAPRO-2 (NCT03395197) trial, evaluating the use of talazoparib and enzalutamide as a combination therapy to treat patients with metastatic, castration-resistant prostate cancer. the combination of talazoparib (a PARP inhibitor) with enzalutamide improved progression-free survival in patients with metastatic castration-resistant prostate cancer. However, a significant number of patients experienced dose interruptions or reductions of talazoparib due to adverse events (AEs), particularly Grade 3 or higher Anemia, Thrombocytopenia, and Neutropenia. This study analyzed data from 412 patients to investigate the relationship between talazoparib exposure and these AEs. They used time-varying average talazoparib concentrations (Cavg,t) and found that higher Cavg,t was associated with a higher risk of these AEs. Other factors like baseline hemoglobin, body weight, and lactate dehydrogenase levels were also linked to increased risk. The findings support a dose modification approach for managing AEs in these patients. Dr Azad stresses the need to find a balance between optimal drug efficacy and treatment-related toxicities such as anemia. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.